Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders.

Prerna Rastogi, Alice Rickard, Nikolay Dorokhov, David J Klumpp, Jane McHowat
Author Information
  1. Prerna Rastogi: Department of Pathology, Saint Louis University School of Medicine, Doisy Research Bldg., 3rd Floor, 1110 S. Grand Blvd., St. Louis, MO 63104, USA.

Abstract

Interstitial cystitis (IC) is associated with increased activated mast cell numbers in the bladder and impairment of the barrier function of the urothelium. We stimulated immortalized urothelial cells derived from the inflamed region of IC bladders (SR22A or SM28 abn) or from healthy bladders (PD07i or PD08i) with tryptase and measured phospholipase A(2) (PLA(2)) activity and the resultant release of arachidonic acid and prostaglandin E(2) (PGE(2)). Tryptase stimulation of either PD07i or SR22A resulted in similar increases in PLA(2) activity and arachidonic acid release. However, tryptase stimulation of SR22A and SM28 abn did not result in a significant increase in PGE(2) release compared with the increase in PGE(2) release from tryptase-stimulated PD07i and PD08i cells. Expression of mRNA for cyclooxygenase-2 and PGE synthase was lower and mRNA for 15-hydroxyprostaglandin dehydrogenase was higher in SR22A compared with PD07i, suggesting that both decreased synthesis and increased metabolism are responsible for the lack of a PGE(2) response in tryptase-stimulated SR22A cells. Since PGE(2) is a cytoprotective eicosanoid, the failure to produce this metabolite in cells isolated from the IC bladder may represent an increased susceptibility to damage by proinfammatory stimuli.

References

  1. Infect Immun. 2001 Nov;69(11):6689-95 [PMID: 11598039]
  2. Urology. 2008 Feb;71(2):346-50 [PMID: 18308117]
  3. Curr Opin Gastroenterol. 2007 Mar;23(2):107-10 [PMID: 17268236]
  4. Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L209-16 [PMID: 11404264]
  5. Curr Urol Rep. 2006 Nov;7(6):440-6 [PMID: 17052438]
  6. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):212-9 [PMID: 14673513]
  7. J Urol. 1992 Oct;148(4):1145-8 [PMID: 1404625]
  8. J Urol. 2002 Oct;168(4 Pt 1):1568-73 [PMID: 12352459]
  9. Br J Urol. 1995 Jul;76(1):94-100 [PMID: 7648070]
  10. J Pharmacol Exp Ther. 2004 Apr;309(1):398-403 [PMID: 14718596]
  11. Am J Pathol. 2003 Mar;162(3):907-23 [PMID: 12598324]
  12. Ann Clin Lab Sci. 1996 Sep-Oct;26(5):451-7 [PMID: 8879363]
  13. Trends Pharmacol Sci. 2002 Apr;23(4):153-5 [PMID: 11931979]
  14. J Urol. 1996 Dec;156(6):2073-8 [PMID: 8911393]
  15. Digestion. 2005;72(2-3):109-18 [PMID: 16172547]
  16. Urology. 2005 Aug;66(2):434-40 [PMID: 16098373]
  17. Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G82-8 [PMID: 12936912]
  18. BMC Physiol. 2007 Mar 30;7:3 [PMID: 17397547]
  19. Am J Physiol Renal Physiol. 2002 Nov;283(5):F944-51 [PMID: 12372769]
  20. J Urol. 2000 Mar;163(3):1009-15 [PMID: 10688040]
  21. Arch Dermatol Res. 1995;287(6):539-45 [PMID: 7487139]
  22. Am J Physiol. 1996 May;270(5 Pt 1):G757-62 [PMID: 8967486]
  23. J Biol Chem. 2007 Apr 20;282(16):11613-7 [PMID: 17329241]
  24. Annu Rev Biochem. 2000;69:145-82 [PMID: 10966456]
  25. Int J Urol. 2005 Oct;12(10):875-80 [PMID: 16323980]
  26. Urology. 2007 Apr;69(4 Suppl):34-40 [PMID: 17462477]
  27. Eur J Pharmacol. 2001 Apr 13;417(3):239-48 [PMID: 11334856]
  28. Urology. 2007 Apr;69(4 Suppl):9-16 [PMID: 17462486]
  29. J Infect Dis. 2002 Dec 1;186(11):1631-8 [PMID: 12447740]
  30. Am J Physiol Lung Cell Mol Physiol. 2001 Mar;280(3):L421-31 [PMID: 11159024]
  31. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13936-41 [PMID: 11717450]
  32. Prostaglandins Leukot Essent Fatty Acids. 2006 May;74(5):309-15 [PMID: 16621493]
  33. J Urol. 2004 Apr;171(4):1554-8 [PMID: 15017219]
  34. BMC Physiol. 2007 Mar 30;7:4 [PMID: 17397548]
  35. J Biol Chem. 2004 Dec 31;279(53):55905-13 [PMID: 15485847]
  36. Curr Eye Res. 1995 Jul;14(7):601-9 [PMID: 7587307]
  37. J Urol. 2005 Jul;174(1):380-5 [PMID: 15947694]
  38. J Urol. 2005 Dec;174(6):2382-7 [PMID: 16280852]
  39. Infect Immun. 2006 Sep;74(9):5106-13 [PMID: 16926402]
  40. J Urol. 2006 May;175(5):1773-6; discussion 1776 [PMID: 16600756]
  41. J Urol. 1994 Sep;152(3):869-73 [PMID: 8051739]

Grants

  1. R01 DK066119/NIDDK NIH HHS
  2. R01 DK066119-04/NIDDK NIH HHS
  3. DK-66119/NIDDK NIH HHS

MeSH Term

Arachidonic Acid
Cadherins
Cell Line
Cyclooxygenase 2
Cystitis, Interstitial
Cytoprotection
Dinoprostone
Enzyme Activation
Gene Expression
Group VI Phospholipases A2
Humans
Hydroxyprostaglandin Dehydrogenases
Intramolecular Oxidoreductases
Keratins
Phospholipases A2
Prostaglandin-E Synthases
Protein Folding
Tryptases
Urinary Bladder
Urothelium
Wound Healing

Chemicals

Cadherins
Arachidonic Acid
Keratins
Hydroxyprostaglandin Dehydrogenases
Cyclooxygenase 2
Group VI Phospholipases A2
PLA2G6 protein, human
Phospholipases A2
Tryptases
Intramolecular Oxidoreductases
Prostaglandin-E Synthases
Dinoprostone

Word Cloud

Created with Highcharts 10.0.02PGEcellsSR22AreleasePD07iICincreasedbladderscystitisbladderimmortalizedurothelialSM28abnPD08itryptasePLAactivityarachidonicacidprostaglandinstimulationincreasecomparedtryptase-stimulatedmRNAInterstitialassociatedactivatedmastcellnumbersimpairmentbarrierfunctionurotheliumstimulatedderivedinflamedregionhealthymeasuredphospholipaseresultantETryptaseeitherresultedsimilarincreasesHoweverresultsignificantExpressioncyclooxygenase-2synthaselower15-hydroxyprostaglandindehydrogenasehighersuggestingdecreasedsynthesismetabolismresponsiblelackresponseSincecytoprotectiveeicosanoidfailureproducemetaboliteisolatedmayrepresentsusceptibilitydamageproinfammatorystimuliLossE2obtainedinterstitialpatient

Similar Articles

Cited By